Shenzhen Neptunus Bioengineering Co., Ltd.

000078.SZ

000078.SZShenzhen Neptunus Bioengineering Co., Ltd. CN flag

Shenzhen

2.38

CNY

-0.09

(-3.64%)

-0.66EPS

-3.61P/E

5.07BMarket Cap

Oct 29Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

Shenzhen Neptunus Bioengineering Co., Ltd.

000078.SZ

(Shenzhen)

Recent

price

2.38

P/E

ratio

-3.61

div

yld

- -

ROIC.AI

Legends:

Stock price

Beta (1.0 Market)

% total return 10/12

Stock

S&P500

-21.19

32.83

-26.32

33.33

-30.81

95.62

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	TTM
1.38	1.66	2.45	3.25	3.93	4.49	5.36	15.19	6.13	9.42	14.51	15.68	15.26	15.62	14.39	13.84	12.57	Revenue per Share
-0.01	0.01	0.03	0.03	0.04	0.07	0.01	0.65	0.19	0.24	0.17	0.08	-0.11	0.04	-0.39	-0.64	-0.66	Basic EPS, GAAP
0.09	0.05	-0.04	-0.18	-0.15	-0.23	-0.19	-0.11	-0.8	-1.02	-0.51	0.79	0.57	0.28	-0.06	-0.2	-0.04	Free Cash Flow per Basic Share
0.05	0.04	0.06	0.07	0.09	0.09	0.12	0.39	0.09	0.06	0.41	0.51	0.29	0.22	0.25	0.21	0.2	Dividend per Share
-0.25	-0.24	-0.22	-0.18	-0.15	-0.02	-0.01	0.65	1.26	1.22	1.38	1.49	1.39	1.42	1.03	0.39	0.4	Book Value per Share
0.4	0.3	0.42	0.45	0.48	0.87	0.78	2.33	2.27	0.95	1.09	1.56	1.76	1.69	1.46	1.1	1.11	Tangible Book Value per Share
1,630	1,631	1,632	1,631	1,632	1,780	1,830	732	2,221	2,648	2,646	2,646	2,623	2,628	2,630	2,631	2,632	Basic Weighted Avg Shares
2,255	2,710	3,999	5,305	6,418	7,993	9,802	11,118	13,606	24,940	38,381	41,493	40,022	41,054	37,835	36,419	33,096	Sales/Revenue/Turnover
-0.33	1.97	4.16	4.28	3.59	3.41	3.73	4.39	5.97	6.43	5.1	5.58	4.57	3.83	2.67	2.43	2.28	Operating Margin (%)
58	54	53	53	61	70	87	80	75	103	131	152	194	269	276	284	- -	Depreciation Expense
-13	14	47	53	59	117	24	475	418	639	448	206	-289	93	-1,027	-1,690	-1,732	Net Income, GAAP
- -	- -	48.68	38.1	6.57	34.17	46.64	17.6	23.7	28.78	30.82	41.25	115.44	55.26	- -	- -	158.21	Effective Tax Rate (%)
-0.57	0.52	1.17	0.99	0.92	1.46	0.24	4.27	3.08	2.56	1.17	0.5	-0.72	0.23	-2.71	-4.64	-5.23	Profit Margin (%)
-40	-430	-223	-15	-73	509	154	740	3,696	2,350	3,058	2,742	1,677	1,855	1,831	1,081	1,161	Working Capital
204	124	62	- -	- -	- -	- -	- -	24	1,703	3,374	1,359	357	377	400	320	386	LT Debt
843	693	903	971	1,057	1,888	1,783	2,143	5,878	6,470	7,158	7,851	7,490	7,308	6,112	4,217	4,250	Total Equity
- -	- -	4.21	5.74	7.53	4.85	4.48	8.47	9.34	10.81	8.13	6.54	-1.3	3.33	- -	- -	- -	Return on Invested Capital (%)
- -	- -	7.95	8	8.7	4.47	1.99	19.11	10.71	8.92	5.72	3.36	-3.56	1.7	- -	- -	55.55	Return on Capital (%)
- -	- -	- -	- -	- -	- -	- -	- -	25.63	21.27	13.02	5.43	-7.61	2.53	-31.86	-90.6	-89.7	Return on Common Equity (%)

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	19.12%	-0.89%	-3.74%
Net Income, GAAP	26.45%	-312.46%	64.56%
Free Cash Flow	181.05%	-46.52%	224.16%
Total Cash Common Dividend	50.56%	-8.91%	-14.55%
Total Equity	16.49%	-8.94%	-31%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Similar Companies: Albert David Limited (ALBERTDAVD.NS)
Delivra Health Brands Inc. (DHBUF)
Biome Grow Inc. (BIOIF)
Grown Rogue International Inc. (GRIN.CN)
Bionoid Pharma Inc. (BINP)
Shield Therapeutics plc (SHIEF)
Business: Shenzhen Neptunus Bioengineering Co., Ltd. researches and develops, manufactures, and sells pharmaceutical products primarily in China. It offers drugs in the fields of anti-tumor, cardio-cerebrovascular, marine drugs, and other fields. The company was founded in 1989 and is based in Shenzhen, China.

	Dec'23	Mar'24	Jun'24
ST Debt	11,078	11,038	10,671
LT Borrowings	200	209	260
LT Finance Leases	120	146	125
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	2,751	2,751	2,751
Market Capitalization	8,636	6,396	5,580

	Dec'23	Mar'24	Jun'24
Total Current Assets	28,809	29,072	28,253
Accounts Receivable, Net	17,357	17,364	16,773
Cash, Cash Equivalents & STI	3,675	3,932	4,126
Inventories	3,679	3,465	3,498
Total Current Liabilities	27,728	28,014	27,091
Payables & Accruals	- -	- -	- -
ST Debt	11,078	11,038	10,671
Deferred Revenue	- -	- -	- -

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	TTM
1.38	1.66	2.45	3.25	3.93	4.49	5.36	15.19	6.13	9.42	14.51	15.68	15.26	15.62	14.39	13.84	12.57	Revenue per Share
-0.01	0.01	0.03	0.03	0.04	0.07	0.01	0.65	0.19	0.24	0.17	0.08	-0.11	0.04	-0.39	-0.64	-0.66	Basic EPS, GAAP
0.09	0.05	-0.04	-0.18	-0.15	-0.23	-0.19	-0.11	-0.8	-1.02	-0.51	0.79	0.57	0.28	-0.06	-0.2	-0.04	Free Cash Flow per Basic Share
0.05	0.04	0.06	0.07	0.09	0.09	0.12	0.39	0.09	0.06	0.41	0.51	0.29	0.22	0.25	0.21	0.2	Dividend per Share
-0.25	-0.24	-0.22	-0.18	-0.15	-0.02	-0.01	0.65	1.26	1.22	1.38	1.49	1.39	1.42	1.03	0.39	0.4	Book Value per Share
0.4	0.3	0.42	0.45	0.48	0.87	0.78	2.33	2.27	0.95	1.09	1.56	1.76	1.69	1.46	1.1	1.11	Tangible Book Value per Share
1,630	1,631	1,632	1,631	1,632	1,780	1,830	732	2,221	2,648	2,646	2,646	2,623	2,628	2,630	2,631	2,632	Basic Weighted Avg Shares
2,255	2,710	3,999	5,305	6,418	7,993	9,802	11,118	13,606	24,940	38,381	41,493	40,022	41,054	37,835	36,419	33,096	Sales/Revenue/Turnover
-0.33	1.97	4.16	4.28	3.59	3.41	3.73	4.39	5.97	6.43	5.1	5.58	4.57	3.83	2.67	2.43	2.28	Operating Margin (%)
58	54	53	53	61	70	87	80	75	103	131	152	194	269	276	284	- -	Depreciation Expense
-13	14	47	53	59	117	24	475	418	639	448	206	-289	93	-1,027	-1,690	-1,732	Net Income, GAAP
- -	- -	48.68	38.1	6.57	34.17	46.64	17.6	23.7	28.78	30.82	41.25	115.44	55.26	- -	- -	158.21	Effective Tax Rate (%)
-0.57	0.52	1.17	0.99	0.92	1.46	0.24	4.27	3.08	2.56	1.17	0.5	-0.72	0.23	-2.71	-4.64	-5.23	Profit Margin (%)
-40	-430	-223	-15	-73	509	154	740	3,696	2,350	3,058	2,742	1,677	1,855	1,831	1,081	1,161	Working Capital
204	124	62	- -	- -	- -	- -	- -	24	1,703	3,374	1,359	357	377	400	320	386	LT Debt
843	693	903	971	1,057	1,888	1,783	2,143	5,878	6,470	7,158	7,851	7,490	7,308	6,112	4,217	4,250	Total Equity
- -	- -	4.21	5.74	7.53	4.85	4.48	8.47	9.34	10.81	8.13	6.54	-1.3	3.33	- -	- -	- -	Return on Invested Capital (%)
- -	- -	7.95	8	8.7	4.47	1.99	19.11	10.71	8.92	5.72	3.36	-3.56	1.7	- -	- -	55.55	Return on Capital (%)
- -	- -	- -	- -	- -	- -	- -	- -	25.63	21.27	13.02	5.43	-7.61	2.53	-31.86	-90.6	-89.7	Return on Common Equity (%)

Year	Q1	Q2	Q3	Q4	FY
2022	9,202	8,920	10,834	8,879	37,835
2023	9,958	9,996	8,687	7,778	36,419
2024	8,088	8,544	- -	- -	- -

Shenzhen Neptunus Bioengineering Co., Ltd.

Growth Rates

(avg. rate of change)

Growth Rates

(avg. rate of change)

Capital Structure

Working Capital

Quarterly Revenue

Year

Quarterly Earnings Per Share

Year

Quarterly Dividends Per Share

Year